1. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
3. Huang H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors (Basel) 2018;18:3249.
4. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer - roles in threat and therapy. Asian Pac J Cancer Prev 2014;15:1085-1091.
5. Singh NK, Quyen DV, Kundumani-Sridharan V, Brooks PC, Rao GN. AP-1 (Fra-1/c-Jun)- mediated induction of expression of matrix metalloproteinase-2 is required for 15S- hydroxyeicosatetraenoic acid-induced angiogenesis. J Biol Chem 2010;285:16830-16843.
6. Gupta S, Kumar P, Kaur H, Sharma N, Saluja D, Bharti AC, Das BC. Selective participation of c-Jun with Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis in tongue cancer. Sci Rep 2015;5:16811.
7. Nanda DP, Dutta K, Ganguly KK, Hajra S, Mandal SS, Biswas J, Sinha D. MMP-9 as a potential biomarker for carcinoma of oral cavity: a study in eastern India. Neoplasma 2014;61:747-757.
8. Pereira AC, Dias do Carmo E, Dias da Silva MA, Blumer Rosa LE. Matrix metalloproteinase gene polymorphisms and oral cancer. J Clin Exp Dent 2012;4:e297-e301.
9. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, Yates B, Bruford E. Genenames.org: the HGNC and VGNC resources in 2019. Nuclic Acids Res 2019;47:D786-D792.
10. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobson A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
12. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Balabhadrapatruni VS, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19:649-658.
13. Vijayashree P, Paramasivam A. Virtual screening of mutations in antioxidant genes and its putative association with HNSCC: An in silico approach. Mutat Res 2020;9:111710 [Epub ahead of print].
14. Anita R, Paramasivam A, Vijayashree Priyadharsini J, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res 2020;10,2546-2554.
15. Liu Y, Li Y, Liu Z, Zhang L, Anniko M, Duan M. Prognostic significance of matrix metalloproteinase-20 overexpression in laryngeal squamous cell carcinoma. Acta Otolaryngol 2011;131:769-773.
16. Nikitakis NG, Gkouveris I, Aseervatham J, Barahona K, Ogbureke KUE. DSPP-MMP20 gene silencing downregulates cancer stem cell markers in human oral cancer cells. Cell Mol Biol Lett 2018;23:30.
17. Aseervatham J, Geetu S, Anunobi CC, Koli K, Ogbureke KUE. Survey of dentin sialophosphoprotein and its cognate matrix metalloproteinase-20 in human cancers. Cancer Med 2019;8:2167-2178.
18. Aseervatham J, Ogbureke KUE. Effects of DSPP and MMP20 Silencing on adhesion, metastasis, angiogenesis, and epithelial-mesenchymal transition proteins in oral squamous cell carcinoma cells. Int J Mol Sci 2020;21:4734.
19. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, Song X, Jin L, Li G, Zheng H. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One 2013;8:e62023.
20. Li Y, Wang Y, Sun H, Zhang Y, Li H, Cong X, Yin W, Song W. Association between matrix metalloproteinase-1, 2, 3 polymorphisms and oral cancer risk: A meta-analysis. Genet Test Mol Biomarkers 2018;22:456-464.
21. de Matos FR, Santos EM, Santos HBP, Machado RA, Lemos TMAM, Coletta RD, Freitas R. Association of polymorphisms in IL-8, MMP-1 and MMP-13 with the risk and prognosis of oral and oropharyngeal squamous cell carcinoma. Arch Oral Biol 2019;108:104547.
22. Lin CW, Yang SF, Chuang CY, Lin HP, Hsin CH. Association of matrix metalloproteinase-11 polymorphisms with susceptibility and clinicopathologic characteristics for oral squamous cell carcinoma. Head Neck 2015;37:1425-1431.
23. Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med 2007;36:409-414.
24. Jain A, Girija A, Arumugam P, Jayaseelan V. A Computational approach to identify the mutations in the genes of the RTK signaling pathway and their possible association with oral squamous cell carcinoma. Middle East J Cancer 2020; [epub ahead of print] doi: 10.30476/mejc.2020.82336.1079.